Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth-Reference-Cited by-同舟云学术

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

Published:2011-09-16 Issue:12 Volume:10 Page:2298-2308
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Yakes F. Michael,Chen Jason,Tan Jenny,Yamaguchi Kyoko,Shi Yongchang,Yu Peiwen,Qian Fawn,Chu Felix,Bentzien Frauke,Cancilla Belinda,Orf Jessica,You Andrew,Laird A. Douglas,Engst Stefan,Lee Lillian,Lesch Justin,Chou Yu-Chien,Joly Alison H.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 1093 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis and pharmacological evaluation of novel thiazole derivatives as c-Met kinase inhibitors and anticancer agents;Journal of Molecular Structure;2024-12

2. ROS1-rearranged non-small cell lung cancer: Understanding biology and optimizing management in the era of new approvals;Current Problems in Cancer;2024-12

3. Hit me with your best shot: Integrated hit discovery for the next generation of drug targets;Drug Discovery Today;2024-10

4. Design, Synthesis, Biological Evaluation and Molecular Modeling Studies of New Aminopyrimidine Derivatives as Potential Anticancer Agents;Journal of Computational Biophysics and Chemistry;2024-09-03

5. FDA-approved small molecule kinase inhibitors for cancer treatment (2001–2015): Medical indication, structural optimization, and binding mode Part I;Bioorganic & Medicinal Chemistry;2024-09